Clene Nanomedicine, Inc.

<div class="infobox infobox-company">
<div class="infobox-header">Clene Nanomedicine, Inc.</div>
<div class="infobox-row"><strong>Headquarters:</strong> Salt Lake City, Utah, USA</div> [@rescueals]
<div class="infobox-row"><strong>Founded:</strong> 2013</div>
<div class="infobox-row"><strong>Public:</strong> NASDAQ (CLNN)</div>
<div class="infobox-row"><strong>Market Cap:</strong> ~$30M USD</div>
</div>

Overview

<div class="infobox infobox-company">
<div class="infobox-header">Clene Nanomedicine, Inc.</div>
<div class="infobox-row"><strong>Headquarters:</strong> Salt Lake City, Utah, USA</div> [@rescueals]
<div class="infobox-row"><strong>Founded:</strong> 2013</div>
<div class="infobox-row"><strong>Public:</strong> NASDAQ (CLNN)</div>
<div class="infobox-row"><strong>Market Cap:</strong> ~$30M USD</div>
</div>

Overview

Clene Nanomedicine, Inc. is a clinical-stage biotechnology company developing nanocatalytic therapeutics for the treatment of neurodegenerative diseases. The company's proprietary platform uses metal-containing nanocrystals to target mitochondrial dysfunction and oxidative stress, which are common pathological features of ALS, multiple sclerosis (MS), Parkinson's disease, and other neurological disorders["@clene"].

Unlike traditional antioxidant approaches that simply scavenge reactive oxygen species, Clene's nanocatalysts work by catalyzing redox reactions within cells, restoring the natural balance of oxidative processes without depleting essential cellular signaling molecules. This novel mechanism of action addresses a fundamental limitation in neuroprotective therapeutics — the need to reduce harmful oxidative damage while preserving the beneficial signaling functions of reactive oxygen species.

Technology Platform

Nanocatalytic Therapeutics

Clene's core technology centers on engineered metal nanocrystals, primarily gold (CNM-Au8), that function as catalytic antioxidants within cells:

• Catalytic Activity: The nanocrystals catalyze the interconversion of reactive oxygen species (ROS) and their reduced forms, maintaining cellular redox homeostasis
• Mitochondrial Targeting: Nanocrystals accumulate in mitochondria, the primary source and target of cellular ROS
• Energy Metabolism: Beyond antioxidant effects, CNM-Au8 has been shown to improve mitochondrial function and ATP production
• Blood-Brain Barrier Penetration: The nanocrystal formulation enables delivery to the central nervous system

Mechanism of Action

CNM-Au8 exerts neuroprotective effects through multiple interconnected pathways:

Pipeline / Products

| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| CNM-Au8 (Gold nanocrystals) | Catalytic antioxidant | ALS / MS | Phase 3 (RESCUE-ALS, REPAIR-MS) | Active |
| CNM-Au8 | Catalytic antioxidant | Parkinson's Disease | Phase 2 (REPAIR-PD) | Active |
| CNM-Au8 | Catalytic antioxidant | Depression | Phase 1 | Active |
| CNM-Au8 | Catalytic antioxidant | Long COVID | Phase 2 | Planning |

Clinical Development

Amyotrophic Lateral Sclerosis (ALS)

CNM-Au8 has advanced through clinical trials for ALS:

Phase 1 Safety Study (2019): Demonstrated safety and tolerability in healthy volunteers and ALS patients[@cnmau].

RESCUE-ALS Phase 2 Trial (2021-2022): A randomized, double-blind, placebo-controlled study in 45 patients with early-stage ALS. The trial met its primary endpoint, showing significant reduction in neurofilament light chain (NfL) levels — a biomarker of neuronal damage — in the treatment arm compared to placebo. Additionally, patients showed trends toward slower functional decline on the ALSFRS-R scale[@rescueals].

HEALEY ALS Platform Trial: CNM-Au8 is being evaluated in the HEALEY ALS Platform Trial, a collaborative effort to accelerate ALS drug development through adaptive trial design.

Multiple Sclerosis

REPAIR-MS Phase 2 Trial (2022-2023): A study evaluating CNM-Au8 in patients with relapsing-remitting MS. Results demonstrated target engagement through improved cerebral energy metabolism as measured by magnetic resonance spectroscopy. The treatment showed favorable effects on myelin integrity markers[@repairms].

Parkinson's Disease

REPAIR-PD Phase 2 Trial (2023): A study in patients with early Parkinson's disease demonstrated that CNM-Au8 improved brain energy metabolism and reduced oxidative stress markers. The trial showed target engagement and biological activity supporting further development in this indication[@repairpd].

Parkinson's Disease

REPAIR-PD Phase 2 Trial (2023): A study in patients with early Parkinson's disease demonstrated that CNM-Au8 improved brain energy metabolism and reduced oxidative stress markers. The trial showed target engagement and biological activity supporting further development in this indication [@repairpd].

NRF2 Pathway Connection:
CNM-Au8's catalytic antioxidant mechanism intersects with the [NRF2-KEAP1 pathway](/mechanisms/nrf2-parkinsons-disease) through indirect activation. By catalyzing the interconversion of reactive oxygen species, CNM-Au8 reduces the overall oxidative stress burden in the [substantia nigra](/brain-regions/substantia-nigra), effectively removing the need for excessive NRF2 suppression by KEAP1. This allows endogenous NRF2 to translocate to the nucleus and activate ARE-driven gene expression more readily.

The relationship between CNM-Au8 and NRF2 signaling in PD:

| Effect | NRF2 Pathway Impact |
|--------|---------------------|
| Reduced superoxide | Decreases KEAP1 oxidation, promotes NRF2 release |
| Improved mitochondrial OCR | Reduces ROS from electron transport chain |
| Lower lipid peroxidation | Preserves neuronal membranes in dopaminergic neurons |
| Enhanced neuronal ATP | Supports active NRF2 translocation machinery |
| Anti-inflammatory | NRF2-mediated suppression of NF-κB in microglia |

CNM-Au8's approach is complementary to direct electrophilic NRF2 activators like [sulforaphane](/companies/evgen-pharma) or [dimethyl fumarate](/companies/biogen), offering a catalytic mechanism that can sustain redox homeostasis without being consumed in the reaction [@lax2021].

[NRF2 Activators for Parkinson's Disease](/mechanisms/nrf2-activators-parkinsons) | [Oxidative Stress in Parkinson's Disease](/mechanisms/oxidative-stress-parkinsons) | [Parkinson's Disease NRF2-KEAP1 Companies](/companies/pd-nrf2-keap1-oxidative-stress-therapy-companies)

Depression

A Phase 1 study has explored CNM-Au8 in major depressive disorder, with plans for further clinical evaluation based on safety and preliminary efficacy signals.

Funding & Financials

Clene has raised capital through public markets to fund its clinical programs:

• 2017: Series C funding round
• 2021: Initial public offering on NASDAQ, raising approximately $40M
• 2022: $30M at-the-market offering program
• 2023: $25M public offering to support ongoing Phase 3 trials
• Current Market Cap: Approximately $30M USD (as of 2026)

Key People

• Mr. Rob Etherington (Chief Executive Officer) — Experienced biotech executive with background in commercial strategy
• Dr. Benjamin R. S. K. L. Liu (President) — Founder focused on nanomedicine platform development
• Dr. Michael T. Hotchkiss (Chief Scientific Officer) — Leads research and pipeline development

Scientific Advisory Board

Clene's scientific advisory board includes leading researchers in neurodegeneration, mitochondrial biology, and nanomedicine, providing strategic guidance on platform development and clinical translation.

Competitive Landscape

Clene's nanocatalytic approach occupies a unique position among neuroprotective therapeutics:

• Traditional Antioxidants: Vitamins, CoQ10, and other compounds have shown limited efficacy in clinical trials, likely due to insufficient targeting and mechanism limitations
• Mitochondrial Modulators: Other companies target mitochondrial dysfunction through different mechanisms (e.g., CPT1 inhibitors, mitochondrial peptides)
• Anti-inflammatory Approaches: Various immunomodulatory strategies in development
• Protein Aggregation Inhibitors: Approaches targeting alpha-synuclein, TDP-43, and other aggregating proteins

Research Partnerships

Clene collaborates with academic institutions and research organizations:

• University of Texas Health Science Center (mitochondrial research)
• Multiple ALS research centers (clinical trial sites)
• National Institutes of Health (biomarker studies)

Future Directions

Clene's development strategy focuses on:

See Also

• [[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)](/diseases/amyotrophic-lateral-sclerosis)
• [[Parkinson's Disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease)
• [Multiple Sclerosis](/diseases/multiple-sclerosis))
• [[Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)](/diseases/neurodegeneration)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction))
• [[Alpha-Synuclein Aggregation](/proteins/alpha-synuclein)](/proteins/alpha-synuclein)
• [Nanomedicine for CNS Disorders](/technologies/nanomedicine-cns))
• [[ALS Treatment Pipeline](/companies/als-pipeline-companies)](/diseases/amyotrophic-lateral-sclerosis)

References